CERNAIS Among the Finalists of StartUp Breeze 2025
We are proud to share that CERNAIS was selected among the finalists of the StartUp Breeze 2025 competition, a national initiative celebrating innovation and entrepreneurship in biotechnology and life sciences.
Although we did not win any prizes this year, the experience was truly valuable. We received excellent feedback from the jury and participants, and several potential investors reached out to us following our presentation – a reminder that sometimes the jury is not always right.
Our Chief Scientific Officer, Gian Tartaglia, represented CERNAIS at the event, presenting the latest company developments and recent research data on Rett Syndrome and CDKL5 Deficiency Disorder (CDD). His talk highlighted our AI-driven RNA-modifying molecule (RMM) platform, which identifies small molecules capable of reactivating silenced genes in rare neurodevelopmental diseases.
Being part of StartUp Breeze 2025 was an inspiring opportunity to connect with other innovators, exchange ideas, and share our vision for the future of RNA-targeted therapeutics. We are grateful to the organizers and to everyone who supported us throughout this journey. The recognition and interest we received reinforce our determination to push boundaries and strengthen collaborations as we continue developing next-generation RNA-based medicines for rare genetic disorders.
